Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0630

-1.6%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LT2011 who wrote (11183)	4/24/2012 5:24:04 PM
From: NTTG	2 Recommendations Read Replies (1) of 13111

No way to know at this point. Really depends on what PVCT tries to get into the trial protocol, and what they do after the first round decision. What I would be looking for: - What are they looking at for dose schedules, and number of eligible lesions? - How many patients patients are they planning to enroll in each arm of the trial? - Are they seriously going to try to position for a 'bystander' effect in the labeling, if so how? The first two are easily adjusted..the third could be a struggle

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next